Connection

Charles Bennett to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Charles Bennett has written about Treatment Outcome.
Charles Bennett
Connection Strength
0.881
Treatment Outcome
  1. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.
    View in: PubMed
    Score: 0.078
  2. Editorial Comment. Urology. 2018 08; 118:125-126.
    View in: PubMed
    Score: 0.065
  3. Racial differences in receipt of adjuvant hormonal therapy among Medicaid enrollees in South Carolina diagnosed with breast cancer. Breast Cancer Res Treat. 2016 05; 157(1):193-200.
    View in: PubMed
    Score: 0.057
  4. Single- versus multiple-tablet HIV regimens: adherence and hospitalization risks. Am J Manag Care. 2016 04; 22(4):242-8.
    View in: PubMed
    Score: 0.056
  5. Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment. JAMA Oncol. 2016 Feb; 2(2):274-6.
    View in: PubMed
    Score: 0.056
  6. Does experience improve hospital performance in treating patients with AIDS? Health Policy. 1993 Apr; 24(1):35-43.
    View in: PubMed
    Score: 0.046
  7. Racial variations in care and outcomes for inpatient HIV-related pneumocystis pneumonia. J Health Care Poor Underserved. 2010 Feb; 21(1):318-33.
    View in: PubMed
    Score: 0.037
  8. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl. 2009 Feb; (112):S20-4.
    View in: PubMed
    Score: 0.034
  9. Intersecting guidelines: administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer. Semin Dial. 2009 Jan-Feb; 22(1):1-4.
    View in: PubMed
    Score: 0.034
  10. Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care. Oncologist. 2007 Aug; 12(8):1019-26.
    View in: PubMed
    Score: 0.031
  11. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost. 2005 Dec; 31(6):681-90.
    View in: PubMed
    Score: 0.028
  12. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2005 Nov 15; 106(10):3343-7.
    View in: PubMed
    Score: 0.027
  13. Agreement between prostate cancer patients and their clinicians about utilities and attribute importance. Health Expect. 2004 Jun; 7(2):115-25.
    View in: PubMed
    Score: 0.025
  14. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Invest. 2001; 19(2):107-13.
    View in: PubMed
    Score: 0.020
  15. Improvements in outcomes of acute respiratory failure for patients with human immunodeficiency virus-related Pneumocystis carinii pneumonia. Am J Respir Crit Care Med. 2000 Aug; 162(2 Pt 1):393-8.
    View in: PubMed
    Score: 0.019
  16. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 1999 Oct 20; 282(15):1453-7.
    View in: PubMed
    Score: 0.018
  17. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999 Sep; 24(5):555-60.
    View in: PubMed
    Score: 0.018
  18. Prostate cancer patients' utilities for health states: how it looks depends on where you stand. Med Decis Making. 1998 Jul-Sep; 18(3):278-86.
    View in: PubMed
    Score: 0.016
  19. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med. 1998 Apr 01; 128(7):541-4.
    View in: PubMed
    Score: 0.016
  20. A comparison of perspectives on prostate cancer: analysis of utility assessments of patients and physicians. Eur Urol. 1997; 32 Suppl 3:86-8.
    View in: PubMed
    Score: 0.015
  21. Interpretation of surrogate endpoints in the era of the 21st Century Cures Act. BMJ. 2016 Dec 30; 355:i6286.
    View in: PubMed
    Score: 0.015
  22. U.S. hospital care for HIV-infected persons and the role of public, private, and Veterans Administration hospitals. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Dec 15; 13(5):416-21.
    View in: PubMed
    Score: 0.015
  23. Patterns of care for HIV-related Pneumocystis carinii pneumonia in a university medical program: a case study. Clin Perform Qual Health Care. 1996 Oct-Dec; 4(4):186-9.
    View in: PubMed
    Score: 0.015
  24. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer. 1996 May 01; 77(9):1854-61.
    View in: PubMed
    Score: 0.014
  25. Score cards for AIDS care. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Jul 01; 9(3):286-90.
    View in: PubMed
    Score: 0.013
  26. The association between race and treatment regret among men with recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2015 Mar; 18(1):38-42.
    View in: PubMed
    Score: 0.013
  27. Economic analyses of clinical trials in cancer: are they helpful to policy makers? Stem Cells. 1994 Jul; 12(4):424-9.
    View in: PubMed
    Score: 0.012
  28. Economic analysis in phase III clinical cancer trials. Cancer Invest. 1994; 12(3):336-42.
    View in: PubMed
    Score: 0.012
  29. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA. 2007 May 09; 297(18):1992-2000.
    View in: PubMed
    Score: 0.008
  30. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol. 2007 Jun; 137(6):545-52.
    View in: PubMed
    Score: 0.008
  31. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007 Apr 20; 25(12):1596-605.
    View in: PubMed
    Score: 0.008
  32. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007 Apr; 39(7):425-9.
    View in: PubMed
    Score: 0.007
  33. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006 May 17; 98(10):708-14.
    View in: PubMed
    Score: 0.007
  34. Patient preferences in prostate cancer: a clinician's guide to understanding health utilities. Clin Prostate Cancer. 2005 Jun; 4(1):15-23.
    View in: PubMed
    Score: 0.007
  35. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst. 2005 Apr 06; 97(7):489-98.
    View in: PubMed
    Score: 0.007
  36. Surgical outcomes of patients with gastric carcinoma: the importance of primary tumor location and microvessel invasion. Surgery. 2003 Oct; 134(4):720-7; discussion 727-9.
    View in: PubMed
    Score: 0.006
  37. Post-cardiac catheterization access site complications and low-molecular -weight heparin following cardiac catheterization. J Invasive Cardiol. 2003 Feb; 15(2):60-2.
    View in: PubMed
    Score: 0.006
  38. Pilot study of a utilities-based treatment decision intervention for prostate cancer patients. Clin Prostate Cancer. 2002 Sep; 1(2):105-14.
    View in: PubMed
    Score: 0.005
  39. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ). 1999 May; (4):i-x, 1-246, I1-36, passim.
    View in: PubMed
    Score: 0.004
  40. Performance measurement in pneumonia care: beyond report cards. Mayo Clin Proc. 1998 Jan; 73(1):5-9.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.